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262 Delivery of dornase alfa from the I-neb® AAD® System
R.W. Potter1, K. Williams1, T.J. Hurren1, R.H. Hatley1. 1Respironics Respiratory
Drug Delivery (UK) Ltd, Chichester, United Kingdom
The I-neb® Adaptive Aerosol Delivery (AAD®) System can deliver precise doses
of DNase[1]. We compared the delivery characteristics of dornase alfa (DNase)
when delivered using the I-neb AAD System and a SideStream® jet nebulizer.
Three I-neb devices and three Sidestream nebulizers were assessed. I-neb devices
were ﬁtted with medication chambers designed to deliver 0.3mL, and run at power
level 10 (of 15). Each device was loaded with DNase (2500U/2.5mL). Particle size
and respirable fraction were assessed using a next generation impactor at 30 L/min.
Delivered dose was assessed using ﬁlters and simulated breathing. Filter contents
were assayed by HPLC (delivered dose) and a DNA-methyl green assay (activity).
For results see Table 1.
Nebulization with the I-neb AAD System did not denature the structure of DNase.
There was a difference in aerosol characteristics between the two nebulizers,
however, the I-neb AAD System had aerosol characteristics which were within
the range of the jet nebulizers used in clinical studies in cystic ﬁbrosis with DNase
(Table 2).
Table 1. DNase delivery characteristics
I-neb AAD System Sidestream jet nebulizer
Delivered dose (mg) 283.3 297.2
Activity (Kunitz units) 267.3 263.4
Mass Median Aerodynamic Diameter (mm) 3.95 2.68
Geometric Standard Deviation 1.87 2.26
Respirable Fraction (%) 64.4 74.6
Table 2. Aerosol characteristics of jet nebulizers approved for use with DNase in comparison with the I-neb AAD System
Pari LC Plus1 Hudson Updraft II1 Marquest Acorn II1 I-neb AAD System Sidestream2
Respirable fraction (%) 47.8 50.5 56.7 64.4 83.0
MMAD (mm) 5.2 4.9 4.1 3.95 2.1
Reference(s)
[1] Potter RW, et al. J Aerosol Med 2006; 19(2): 235.
[2] Fiel SB, et al. Chest 1996; 108: 153–156.
[3] Geller DE, et al. Ped Pulmonol 1998; 25: 83−87.
263 The I-neb® AAD® System has a negligible effect on the increase
in osmolarity of saline over the course of nebulization compared
with a jet nebulizer
R.W. Potter1, K. Williams1, R.H. Hatley1. 1Respironics Respiratory Drug Delivery
(UK) Ltd, Chichester, United Kingdom
Introduction: Evaporation during nebulization is a well known phenomenon when
using jet nebulizers. This tends to create hyperosmolar aerosols, which may cause
bronchoconstriction. The I-neb® Adaptive Aerosol Delivery (AAD®) System is a
nebulizer that utilizes a vibrating mesh technology. We hypothesized that the I-neb
AAD System would not cause a change in the osmolarity of a 0.45% saline solution
compared with a jet nebulizer (LC Plus) over the course of nebulization.
Method: One I-neb device and one LC Plus nebulizer were washed and dried
prior to testing. The I-neb device was ﬁtted with a 1.5mL medication chamber
and set to operate at power level 10, then weighed and ﬁlled with 1.5mL 0.45%
saline. The jet nebulizer was loaded with 4 mL 0.45% saline and run using 6
L/min air. Each device was run on a Harvard respirator set to produce simulated
breathing (Vt = 500mL, f = 15 bmp, I:E = 1:1). Each device was run until the end of
nebulization, deﬁned as the end of treatment buzzer for I-neb, and the sputtering
point +60 s for the jet nebulizer. Each test was performed in triplicate.
Results: The saline concentration in the I-neb AAD System was 4.52mOsm before
nebulization, and 4.63mOsm at the end of nebulization. This compared with
4.52mOsm and 5.69mOsm, respectively, for the jet nebulizer. The change in saline
concentration in the I-neb AAD System was negligible (2.5%) compared with the
change with the jet nebulizer (26%).
Conclusions: The tonicity of solution loaded into the I-neb AAD System stays
almost constant over the course of a treatment.
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It has been shown that ﬂuticasone propionate and salmeterol inhibit inﬂammatory
responses in vitro and in vivo, at least in animal models, and that salmeterol
increases CFTR expression in human airway epithelial cells. Although inhaled
association of salmeterol-ﬂuticasone propionate (SFP) is frequently used in CF
patients, its clinical beneﬁt remains unclear. In order to evaluate the effects of
inhaled SFP on lung and epithelial cell functions in CF children, a double blind
crossover study was performed in 20 children (6−18 y). The two periods of 168
days treatment (<12 y: SFP 50/100mg bid, >12 y: 50/250mg bid, vs placebo)
were separated by a 6 weeks washout period. Clinical parameters, lung function,
quantiﬁcation of inﬂammatory mediators in sputum (IL-8, MMP9, elastase, TIMP-
1) and nasal potential difference (NPD) measurement (basal, amiloride, low chloride
solution) were performed before treatment, 28 days after its beginning (D28) and at
its end (D168). Before treatment, clinical parameters, FEV1 and NDP, were similar
in SFP and placebo groups. At D28, FEV1 was not signiﬁcantly higher in SFP than
in placebo group (87.1±25.4 vs 79.6%±23.1, p = 0.18) and IL-8, MMP9, elastase,
TIMP-1 in sputum and NPD were not different between the two groups. At D168,
FEV1 was higher in SFP than in placebo group (91.2%±22 vs 82%±23), and the
difference was not far from signiﬁcant (p = 0.06). IL-8, MMP9, elastase, TIMP-1
in sputum and NPD were not different between the two groups. Further study with
more patients is necessary to conﬁrm the tendency of FEV1 to increase in CF
children treated with inhaled SFP.
Supported by: Vaincre la mucoviscidose, CHU Reims, GlaxoSmithKline.
265 Long term effects of inhaled tobramycin (TOBI®) in
cystic ﬁbrosis patients
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Background: Respiratory disease is the major cause of morality in cystic ﬁbrosis
(CF) patients and inhaled antibiotic therapy may contribute to the stabilisation of
lung function.
The aim of this study was to evaluate the effect of long term intermittent treatment
with TOBI in CF patients.
Materials and Methods: 17 patients with CF and chronic P. aeruginosa infection
aged 6 to 18 years were qualiﬁed for treatment with inhaled tobramycin. Pulmonary
function, weight and height, clinical status, chest X-ray and occurrence of adverse
events were continually monitored. After active three years treatment period results
of all measured parameters were compared with their previous results (three
years period before treatment with tobramycin). The third year of the study was
observational.
Results: After three years period of treatment we observed FEV1 % predicted
decline by (median value with lower and upper quartile) 2.87% with −10.13 and
3.67 from baseline values. During TOBI therapy the deterioration of lung function
was signiﬁcantly lower (p = 0.03) than in the period before treatment.
During 3 years period before TOBI therapy median BMI increased by 0.5 kg/m2
with 0.11 and 0.62. After 3 years of treatment median BMI increased signiﬁcantly
(p = 0.02) by 1.19 kg/m2 with 0.31 and 1.89.
TOBI treatment signiﬁcantly delayed progression of pulmonary X-ray changes
assessed by Brasﬁeld score (p = 0.01).
Conclusion: Treatment with nebulised tobramycin reduced pulmonary function
decline, delayed progression of pulmonary X-ray changes and improved nutritional
status in CF patients over three-years period of treatment.
Supported by: Novartis Poland.
